b'MRD testing by Next-GenerationSequencing (NGS) is a proven tool in the development of management strategiesfor hematologic malignancies.A number of investigators have described NGS-based approaches that have demonstrated success in detecting and monitoring MRD in Chronic Lymphocytic Leukemia (CLL), Acute Lymphoblastic Leukemia (ALL) and other lymphoid malignancies. 1,2LymphoTrack Assays are NGS-based deep sequencing assays that detect virtually all clonal rearrangements within targeted T-cell receptor (TCR) or immunoglobulin (Ig) antigen receptor loci. Once a specific rearrangement (the clonotype) has been identified, LymphoTrack assays can be used to track these clonotype populations to a sensitivity as low as 10 -6 . Complementing the LymphoTrack Assays, the LymphoTrack MRD solution is a bundled product set for improved Minimal Residual Disease (MRD) assessment and tracking of rearrangement (clonotype) sequences. LymphoTrack MRD B-cell and T-cell bundles offer a complete MRD solution for clonality tracking. B- or T-cell bundles may be purchased that include the LymphoTrack Assay, LymphoTrack MRD Bioinformatics Software, a LymphoTrack Low Positive Control and a LymphoQuant Internal Control. Each bundle facilitates the standardization of MRD testing by providing controls suitable for longitudinal MRD tracking with test sensitivity assurance. LymphoTrack MRD Software further simplifies clonal tracking due to rich sequence specific data analyses. This software enables longitudinal monitoring of clonal populations by providing multiple functionalities to the user including project planning features and automated bioinformatics applications. When monitoring MRD, a highly sensitive detection method such as NGS-based LymphoTrack may aid in the early detection of lymphoproliferative disease relapse. However, MRD test results are dependent on DNA amounts interrogated, as well as the confidence level of the test. Controls tracking MRD test sensitivity are thus necessary when reporting MRD test results. Designed for MRD testing, the LymphoTrack Low Positive Control confirms the sensitivity of respective LymphoTrack MRD runs match or exceed a10 -4(or 1 in 10,000) level. Detection of the LymphoTrack Low Positive Control thus lessens false negative reporting concerns at 10 -4 , and is further necessary to report MRD negative results with confidence at 10 -4 . Consistent use of a spike-in internal control promotes objective monitoring of clonality over time enabling test standardization.To serve this need, Invivoscribe offers a LymphoQuant B-cell and T-cell Internal Control. Addition of a spike-in LymphoQuant B-cell or T-cell Internal Control to samples allows for the estimation of clonotype cell equivalents to facilitate longitudinal clonotype tracking over time.References:1Leukemia 27:1659-1665, 2013.2Blood 120:5173-5180, 2012.Invivoscribe 2020|51'